contact

Management & Scientific Team

Michael Mullan, M.B.B.S., Ph.D.
Chief Executive Officer & Chief Scientific Officer

Michael Mullan, M.B.B.S., Ph.D., has served as the Chief Executive Officer and Chief Scientific Officer for Archer Pharmaceuticals since its inception in 2008. He is also Chairman of the Archer Board. Dr. Mullan has previously served as CEO or CSO of both publicly traded and private drug development companies including the Roskamp Institute which he co-founded in 2003.

Prior to becoming a US citizen, Dr. Mullan trained and worked in London, UK, where he co-discovered (and was co-inventor of the patents covering) the first-known genetic causes of Alzheimer's disease in the amyloid gene.

Throughout his career, Dr. Mullan has received several major grants and contracts from both private and federal organizations to work on the causes and cures of Alzheimer’s disease.

Dr. Mullan earned his medical degree from The Royal Free Hospital Medical School, University of London and his Ph.D. in the molecular genetics of Alzheimer's Disease from St.Mary's Hospital Medical School, University of London.

 

Fiona Crawford, Ph.D.
Chief Technical Officer & Associate Chief Scientific Officer

Fiona Crawford, Ph.D., is the Chief Technical Officer and Associate Chief Scientific Officer for Archer Pharmaceuticals, Inc. in Sarasota, Florida. She also serves on the Board of Archer.

Dr. Crawford is from Belfast, Northern Ireland, and her Ph.D. training was in London, England, where she was a part of the team that identified the first Alzheimer’s mutations. Dr. Crawford has 30 years of experience in the field of research and development for Alzheimer’s disease and related disorders, and is the CEO of the Roskamp Instituet, which she co-founded with Dr. Mullan.

Throughout her career, Dr. Crawford has received and managed numerous grants and contracts for neuroscience research, leading collaborative teams of scientists in preclinical and translational research projects. She has published over 160 peer-reviewed manuscripts on Alzheimer’s Disease, Traumatic Brain Injury, Gulf War Illness, and other neurodegenerative and neuropsychological conditions.

Dr. Crawford is a molecular geneticist and molecular biologist trained at the Queen’s University of Belfast in Northern Ireland, and St. Mary’s Hospital Medical School in London, England.

 

Park A. Dodd, III, CPA
Chief Financial Officer

Mr. Dodd has over 30 years of financial experience with Consumer Products, Bio-tech and Manufacturing companies. He has severed as CFO, Secretary and Treasurer in public and private companies. Mr. Dodd’s experience includes financial reporting, management reporting, strategic financial planning, information technology management and other operational functions.

He has served in various financial positions with KPMG, Philip Morris USA, Capital One Financial, Inc. and Tatum LLC., a national executive services firm that specializes in providing interim senior financial leadership to client organizations, and Rock Creek Pharmaceuticals, Inc.

His consulting clients have included Belk Department Stores, United State Olympic Committee and Trinity College in Hartford, CT. Mr. Dodd received an undergraduate degree in Accounting from Virginia Tech in 1975 and an MBA from Virginia Commonwealth University in 1986. He is a licensed Certified Public Accountant in the State of Virginia.

 

Steven Ford
Regulatory Consultant

Steven Ford is the regulatory consultant for Archer Pharmaceuticals, Inc. Dr. Ford is an independent regulatory affairs and pharmaceutical product development consultant.

Dr. Ford has more than 20 years of experience in the biopharmaceutical industry, and has worked on several development teams to take four products from concept to marketing approval. Dr. Ford has filed more than 20 marketing applications and has covered development of drug delivery systems, novel designer proteins, monoclonal antibodies and cellular therapies, as well as medical device products.

Prior to Archer, Dr. Ford was the vice president of product development at Chimeric Therapies, Inc. He also worked at Amgen, Inc. in North America and Ethical Pharmaceuticals, Ltd. in the United Kingdom.

Dr. Ford received his Ph.D. in microbial biochemistry from the University of Southampton in England.

Lead Scientists

Ghania Ait-Ghezala, Ph.D.
Head of Genetics and Genomics

Dr. Ait-Ghezala obtained her Bachelor's degree in Molecular Biology from the University of Science and Technology in Algeria, and her Masters and Ph.D. in Molecular and Human Genetics from the University of Paris. She has over 25 years of experience in genetic analyses and gene manipulation, including the investigation of genetic risk factors in clinical samples, as well as genetic engineering of specific cell types for implementation as screening platforms.

Venkat Mathura, Ph.D.
Picture of Venkat Mathura
Head of Bioinformatics and Cheminformatics

Dr. Mathura is responsible for virtual screening, computational drug design, in silico lead optimization and molecular modeling. His Bachelor’s degree in Biotechnology is from Anna University in Chennai, India, and his Ph.D. in Bioinformatics and Computational Biology is from the University of Texas Medical Branch in Galveston. Dr. Mathura has developed customized platforms for in-house and remote management of clinical data, as well as laboratory information management systems to consolidate and analyze preclinical data from diverse disciplines.

Daniel Paris, Ph.D.
Daniel Paris
Head of Research & Development

Dr. Paris leads a team of multidisciplinary scientists focused on identifying molecular targets and developing in vitro and in vivo screens for Alzheimer’s disease. In addition, he is in charge of preclinical development and testing of the lead compounds in Archer’s pipeline.

Dr. Paris received his Ph.D. in Molecular and Cellular Biology from the University of Paris and has nearly 30 years of experience in neurodegenerative disease research, with a particular focus on Alzheimer’s Disease and identification and validation of drug targets. He is an inventor on several patents on novel therapeutic approaches for Alzheimer’s Disease and related disorders.